Gemcitabine and docetaxel treatment trial#

Response was evaluated after every 2 cycles of therapy. Radiological response was evaluated according to RECIST 1.1. The presence of the t(X 18) translocation was also confirmed. Statistical and KaplanвЂ“Meier analyses were performed using GraphPad Prism version 7.0 (GraphPad Software, La Jolla, California, USA).ДЄn experienced soft tissue pathologist confirmed the diagnosis of synovial sarcoma in all cases. Progression-free survival was defined as time from first dose of gemcitabine/docetaxel to date of disease progression and overall survival as time from first dose of gemcitabine/docetaxel to death from any cause. Data regarding baseline characteristics, treatment received, response assessments and treatment toxicities were retrospectively collected from the electronic patient record. All patients with a histological diagnosis of synovial sarcoma treated with at least one cycle of gemcitabine/docetaxel chemotherapy between 20В at the Royal Marsden Hospital and 20В at the Vanderbilt-Ingram Cancer Centre were identified using the unit database and pharmacy records. Institutional Review Board approval was obtained prior to commencing the study. We reviewed the use of gemcitabine/docetaxel in relapsed synovial sarcoma in patients from two tertiary cancer centres at the Royal Marsden Hospital in London and at the Vanderbilt-Ingram Cancer Centre in Nashville, to assess any activity in this setting. Consequently, the aim of this study was to evaluate the efficacy and safety of this combination in synovial sarcoma. However, there are currently few data regarding the role of gemcitabine/docetaxel specifically in synovial sarcoma. Retrospective studies have suggested that this subtype is particularly sensitive to ifosfamide chemotherapy. It has a characteristic translocation t(X 18 p11.2 q11.2).

This tumour tends to occur in the extremities in adolescents and young adults. Synovial sarcoma is an uncommon type of sarcoma, representing approximately 2.5% of all soft tissue sarcomas. In addition, a number of other agents have recently been approved for treating advanced soft tissue sarcomas, including pazopanib, trabectedin, olaratumab and eribulin. Over the last few years, gemcitabine and docetaxel combination chemotherapy has emerged as an effective salvage schedule, particularly in leiomyosarcoma and undifferentiated pleomorphic sarcoma. First-line chemotherapy for metastatic disease consists of an anthracycline-based regimen. The outcome of patients with metastatic soft tissue sarcoma is poor with a median overall survival of 12вЂ“18В months. Despite optimal treatment, approximately 50% of patients with high-grade tumours will develop recurrent or metastatic disease. The mainstay of management for localized disease is complete surgical resection with or without (neo)adjuvant radiation. They account for about 1% of adult cancers and 15% of paediatric tumours.

Soft tissue sarcomas are a heterogeneous group of rare tumours of mesenchymal origin.

Gemcitabine and docetaxel treatment trial#

Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not be offered to this patient group outside a clinical trial context. Treatment was not discontinued due to toxicity. Toxicities reported were as expected for this chemotherapy combination. The response rate was 5% with a median progression-free survival of 2 months (95% CI 1.3вЂ“3.7). Twenty one patients were treated with gemcitabine/docetaxel, the majority as a second- or third-line treatment for metastatic disease. Treatment response, toxicity and outcome data were collected. We identified patients treated with gemcitabine/docetaxel between 20 in a UK and a US oncology centre using retrospective pharmacy and medical records. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options.